Markey Researcher Directory

« Search for another researcher

Research Focus

Phase I investigations, lung cancer, head and neck cancer, radiation-chemotherapy interactions, population studies in Appalachia

Contact Information

CC457
800 Rose Street
University of Kentucky
Lexington Kentucky 40536
View active clinical trials by this investigator

Key Publications

Please refer to the PubMed listing below.

Recent Publications

(five most recent publications via an automated list from PubMed, based on researcher’s ID and the University of Kentucky)
  1. Stocke NA, Sethi P, Jyoti A, Chan R, Arnold SM, Hilt JZ, Upreti M.
    Toxicity evaluation of magnetic hyperthermia induced by remote actuation of magnetic nanoparticles in 3D micrometastasic tumor tissue analogs for triple negative breast cancer.
    Biomaterials. 2017 Mar;120:115-125.
  2. Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.
    Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
    Invest New Drugs. 2017 Feb 16.
  3. Stewart RL, Carpenter BL, West DS, Knifley T, Liu L, Wang C, Weiss HL, Gal TS, Durbin EB, Arnold SM, O'Connor KL, Chen M.
    S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
    Oncotarget. 2016 Jun 07;7(23):34630-42.
  4. Stocke NA, Arnold SM, Hilt JZ.
    Responsive Hydrogel Nanoparticles for Pulmonary Delivery.
    J Drug Deliv Sci Technol. 2015 Oct 01;29:143-151.
  5. Silver NL, Arnold SM, Gleason JF, Kudrimoti M, Brill Y, Dressler EV, Valentino J.
    p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.
    Ann Otol Rhinol Laryngol. 2015 Sep;124(9):714-20.